APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Price, Forecast & Analysis
TSX:APLI • CA03783R1073
APLI.CA Key Statistics, Chart & Performance
The current stock price of APLI.CA is 0.02 CAD. In the past year, price decreased by -42.86%.
APLI.CA Technical Analysis
APLI.CA Financial Highlights
Over the last trailing twelve months APLI.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 30.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -347.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APLI.CA Forecast & Estimates
APLI.CA Ownership
APLI.CA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| BHC | BAUSCH HEALTH COS INC | 1.42 | 3.008B | ||
| CRON | CRONOS GROUP INC | 37.51 | 1.414B | ||
| TLRY | TILRAY BRANDS INC | N/A | 1.258B | ||
| DHT-UN | DRI HEALTHCARE TRUST | 7.09 | 891.583M | ||
| WEED | CANOPY GROWTH CORP | N/A | 658.585M | ||
| GUD | KNIGHT THERAPEUTICS INC | 134.24 | 640.758M | ||
| NGEN | NERVGEN PHARMA CORP | N/A | 470.282M | ||
| TSND | TERRASCEND CORP | N/A | 386.152M | ||
| CPH | CIPHER PHARMACEUTICALS INC | 28.18 | 368.33M | ||
| ACB | AURORA CANNABIS INC | 14.94 | 292.057M |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Toronto Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the Canadian exchanges | Find stocks with similar Fundamental rating on the Canadian exchanges | Find the competitors with the best technical ratings on the Canadian exchanges | Find the competitors with the best fundamentals on the Canadian exchanges | Find the competitors with the best valuation on the Canadian exchanges | Find the competitors with the best dividend on the Canadian exchanges | Find the competitors with the best analyst ratings on the Canadian exchanges
About APLI.CA
Company Profile
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Company Info
APPILI THERAPEUTICS INC-CL A
#21-1344 Summer Street
Halifax NOVA SCOTIA B3H 0A8 CA
CEO: Armand Balboni
Employees: 7
Phone: 19024424655
APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ
What does APPILI THERAPEUTICS INC-CL A do?
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
What is the stock price of APPILI THERAPEUTICS INC-CL A today?
The current stock price of APLI.CA is 0.02 CAD.
Does APLI stock pay dividends?
APLI.CA does not pay a dividend.
What is the ChartMill rating of APPILI THERAPEUTICS INC-CL A stock?
APLI.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists APLI stock?
APLI.CA stock is listed on the Toronto Stock Exchange exchange.
What sector and industry does APPILI THERAPEUTICS INC-CL A belong to?
APPILI THERAPEUTICS INC-CL A (APLI.CA) operates in the Health Care sector and the Pharmaceuticals industry.
When does APPILI THERAPEUTICS INC-CL A (APLI.CA) report earnings?
APPILI THERAPEUTICS INC-CL A (APLI.CA) will report earnings on 2026-02-17.